{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T04:15:53Z","timestamp":1649218553010},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2007,10,26]],"date-time":"2007-10-26T00:00:00Z","timestamp":1193356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s00108-007-1959-x","type":"journal-article","created":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T06:14:29Z","timestamp":1193206469000},"page":"1343-1348","source":"Crossref","is-referenced-by-count":2,"title":["Therapie des multiplen Myeloms"],"prefix":"10.1007","volume":"48","author":[{"given":"D.","family":"Peest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,26]]},"reference":[{"key":"1959_CR1","doi-asserted-by":"crossref","unstructured":"Alexander DD, Mink PJ, Adami HO et al. (2007) Multiple myeloma: a review of the epidemiologic literature Int J Cancer (Supp 12) 120: 40\u201361","DOI":"10.1002\/ijc.22718"},{"key":"1959_CR2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"Alexanian","year":"1969","unstructured":"Alexanian R, Haut A, Khan AU et al. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208: 1680\u20131685","journal-title":"JAMA"},{"key":"1959_CR3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bmt.1704289","volume":"32","author":"Alyea","year":"2003","unstructured":"Alyea E, Weller E, Schlossman R et al. (2003) Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 32: 1145\u20131151","journal-title":"Bone Marrow Transplant"},{"key":"1959_CR4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"Attal","year":"1996","unstructured":"Attal M, Harrousseau JL, Facon T et al. (1996) Intergroupe francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 335: 1844\u20131845","journal-title":"N Engl J Med"},{"key":"1959_CR5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"Barlogie","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P et al. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98: 492\u2013494","journal-title":"Blood"},{"key":"1959_CR6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L et al. (1996) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. N Engl J Med 334: 488\u2013493","journal-title":"N Engl J Med"},{"key":"1959_CR7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102: 1115\u20131123","journal-title":"Br J Haematol"},{"key":"1959_CR8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F et al. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356: 1110\u20131120","journal-title":"N Engl J Med"},{"key":"1959_CR9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al. (2003) High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 348: 1875\u20131883","journal-title":"N Engl J Med"},{"key":"1959_CR10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G et al. (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12: 991\u2013995","journal-title":"Ann Oncol"},{"key":"1959_CR11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/sj.thj.6200312","volume":"4","author":"Durie","year":"2003","unstructured":"Durie BG, Kyle RA, Belch A et al. (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4: 379\u2013398","journal-title":"Hematol J"},{"key":"1959_CR12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"Durie","year":"1975","unstructured":"Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842\u2013854","journal-title":"Cancer"},{"key":"1959_CR13","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG et al. (2005) International staging system for multiple myeloma. J Clin Oncol 23: 3412\u20133420","journal-title":"J Clin Oncol"},{"key":"1959_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1705194","volume":"37","author":"Hari","year":"2006","unstructured":"Hari P, Pasquini MC, Vesole DH (2006) Cure of multiple myeloma \u2013 more hype, less reality. Bone Marrow Transplant 37: 1\u201318","journal-title":"Bone Marrow Transplant"},{"key":"1959_CR15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","volume":"13","author":"Koreth","year":"2007","unstructured":"Koreth J, Cutler CS, Djulbegovic B et al. (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13: 183\u2013196","journal-title":"Biol Blood Marrow Transplant"},{"key":"1959_CR16","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","volume":"100","author":"Kr\u00f6ger","year":"2002","unstructured":"Kr\u00f6ger N, Sayer HG, Schwerdtfeger R et al. (2002) Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100: 3919\u20133924","journal-title":"Blood"},{"key":"1959_CR17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","volume":"340","author":"Lahtinen","year":"1992","unstructured":"Lahtinen R, Laakso M, Palva I et al. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 340: 1049\u20131052","journal-title":"Lancet"},{"key":"1959_CR18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","volume":"100","author":"McCloskey","year":"1998","unstructured":"McCloskey EV, MacLennan IC, Drayson MT et al. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100: 317\u2013325","journal-title":"Br J Haematol"},{"key":"1959_CR19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2: 822\u2013824","journal-title":"Lancet"},{"key":"1959_CR20","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma","year":"1998","unstructured":"Myeloma Trialists\u2018 Cooperative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16: 3832\u20133842","journal-title":"J Clin Oncol"},{"key":"1959_CR21","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT et al. (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104: 3052\u20133057","journal-title":"Blood"},{"key":"1959_CR22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609\u20132617","journal-title":"N Engl J Med"},{"key":"1959_CR23","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063\u20133067","journal-title":"Blood"},{"key":"1959_CR24","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487\u20132498","journal-title":"N Engl J Med"},{"key":"1959_CR25","first-page":"377","volume":"7","author":"Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377\u2013387","journal-title":"Cancer J"},{"key":"1959_CR26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","volume":"87","author":"Tricot","year":"1996","unstructured":"Tricot G, Vesole DH, Jagannath S et al. (1996) Graft-versus-myeloma effect: proof of principle. Blood 87: 1196\u20131198","journal-title":"Blood"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1959-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-007-1959-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1959-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T10:19:19Z","timestamp":1587982759000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-007-1959-x"}},"subtitle":["Indikationen und M\u00f6glichkeiten"],"short-title":[],"issued":{"date-parts":[[2007,10,26]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["1959"],"URL":"https:\/\/doi.org\/10.1007\/s00108-007-1959-x","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,26]]}}}